Tumor necrosis factor-alpha (TNF-a) is involved in the pathogenesis of several inflammatory
diseases such as rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, and …

Newer TNF blockers (etanercept, infliximab and adalimumab) have contributed greatly to the
control of chronic inflammatory disease. Many of the damaging inflammatory mechanisms …

Tumor necrosis factor (TNF) is a proinflammatory cytokine that has a key role in the
pathogenesis of a variety of autoimmune diseases—including rheumatoid arthritis—and is …

Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …

Cases of active tuberculosis have been reported worldwide with the use of therapeutic
agents that inhibit tumour necrosis factor (TNF) α. TNFα has a central role in mycobacterial …

Treatment of chronic inflammatory conditions, such as rheumatoid arthritis and Crohn9s
disease, with tumor necrosis factor (TNF) targeted biologics is associated with an increased …

Over the last 12 years, TNF antagonists have been successfully used for the treatment of
numerous patients afflicted by chronic inflammatory disorders. However, data from clinical …

This review evaluates the risk of tuberculosis (TB), adherence with recommendations for TB
prevention, and host-related risk in patients with rheumatoid arthritis (RA), psoriatic arthritis …

We review the global experience of infections in patients treated with tumour necrosis factor
(TNF)-α inhibitors, which shows that the overall incidence of severe infections is at least …

Anti-tumor necrosis factor-α (TNF-α) biological agents, including soluble TNF-α receptors
and anti-TNF-α monoclonal antibodies, bring new hope for treating rheumatic diseases such …